(UroToday.com) The 2025 PSMA and Beyond annual meeting featured new developments in genitourinary radioligand therapy session and a presentation by Dr. Robert Flavell discussing STEAP1, DLL3, and CD46 ...

(UroToday.com) The 2026 GU ASCO annual meeting featured a testicular cancer session and a presentation by Dr. Jennifer King discussing a phase II trial of cabozantinib in relapsed refractory germ cell ...

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a surgical and non-surgical treatment of non muscle invasive bladder cancer session and a presentation by Dr.

At the 2026 UCSF-UCLA PSMA Conference, Lisa Bodei reviews PSMA response biomarkers for lutetium PSMA therapy. She presents data from the TheraP and VISION trials showing that baseline SUV mean, ...

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a urology trials in bladder and prostate cancer session and a presentation by Dr. Yi-Jun Shen discussing HERO, a ...

ASCO 2025 Press Releases Johnson & Johnson Leads with First PARP Inhibitor Combo to Improve Efficacy in Patients with HRR-altered mCSPC ImmunityBio Receives FDA Expanded Access Authorization for ...

(UroToday.com) The 2026 PSMA & Beyond conference featured a clinical development session and presentation by Dr. William Maguire discussing regulatory considerations related to PSMA PET imaging in ...

AUA 2025 Upper Tract Urothelial Carcinoma AUA 2025: Phase II Study of Tislelizumab as Neoadjuvant Treatment for Cisplatin-Ineligible High Risk Upper Tract Urothelial Carcinoma AUA 2025: Long-Term ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured an advancements in upper tract urothelial carcinoma session and a presentation by Dr. Savio Domenico Pandolfo ...

(UroToday.com) The 2026 PSMA & Beyond conference featured a clinical development session and presentation by Dr. Jeremie Calais discussing a review of phase 1/2 compounds recently published. Without ...

Lee et al, 1 comprising authors from a number of institutions, published a retrospective observational study conducted on 147 consecutive patients who underwent endoscopic enucleation of the prostate ...